Brian D Radbill, MD
img_Brian D Radbill
ASSOCIATE PROFESSOR | Medicine, Nephrology
Are you a patient?
Specialties
Nephrology, Internal Medicine
Frequent Hemodialysis Network (FHN): Short Daily Dialysis Study

Previously published data suggests that short daily hemodialysis (2-2.5 hours a day, 6 days a week) may be superior to conventional hemodialysis (3-4 hours a day, 3 days a week) in terms of solute clearance and fluid management. Daily hemodialysis could result in improved dialysis adequacy, improved blood pressure control, decreased cardiac disease (specifically, left ventricular hypertrophy), and decreased mortality. We are working with RRI (Renal Research Institute) as part of a multi-center NIH funded clinical trial studying the potential benefits of short daily hemodialysis versus conventional hemodialysis.

The role of matrixmetalloproteinases (MMPs) in renal interstitial fibrosis

Renal interstitial fibrosis (RIF) is the end result of chronic kidney disease (CKD) and is predictive of long-term renal survival and its inhibition might delay progression towards end-stage renal disease (ESRD). Since type IV collagen-rich extracellular matrix is replaced by type-1 collagen after injury, the hypothesis is being tested that matrix metalloproteinase-2 (MMP-2), a type IV collagenase, may play a causative role in renal fibrosis. Mechanistic studies are underway using an MMP-2 -/- mouse to determine whether MMP-2 promotes renal tubular epithelial-mesenchymal transition (EMT), myofibroblast proliferation and fibrogenesis with and without unilateral ureteral obstruction (UUO), a murine model of RIF.

In addition, the role of MMP-2 in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) is under study comparing MMP-2 and fibrognesis marker gene and protein expression by human ADPKD epithelia versus normal renal tubular cell lines in vitro.

BA, University of Michigan

MD, Hahnemann University School of Medicine

MD, Drexel University College of Medicine

Mount Sinai School of Medicine

Mount Sinai School of Medicine

Internship, Internal Medicine, Mount Sinai Hospital

Residency, Nephrology, Mount Sinai Hospital

Fellowship, Nephrology, Mount Sinai Hospital

Certifications

American Board of Internal Medicine

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Radbill has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.